| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1740774512465495 |
| P953 | full work available at URL | https://journals.sagepub.com/doi/full-xml/10.1177/1740774512465495 |
| https://journals.sagepub.com/doi/pdf/10.1177/1740774512465495 | ||
| P698 | PubMed publication ID | 23171499 |
| P2093 | author name string | Edward Whalen | |
| Jesse A. Berlin | |||
| Juergen Kuebler | |||
| H. Amy Xia | |||
| Carol E. Koro | |||
| Brenda J. Crowe | |||
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 | ||
| A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis | Q30669346 | ||
| Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head | Q30670986 | ||
| What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data | Q30926358 | ||
| The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group | Q32062983 | ||
| Comparison of Meta-Analysis Versus Analysis of Variance of Individual Patient Data | Q32067832 | ||
| Use of the false discovery rate for evaluating clinical safety data | Q33203769 | ||
| Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team | Q33511715 | ||
| Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses | Q33947262 | ||
| Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials | Q34619977 | ||
| Why sources of heterogeneity in meta-analysis should be investigated | Q36888653 | ||
| Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants | Q37246423 | ||
| Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations | Q37924038 | ||
| A basic introduction to fixed-effect and random-effects models for meta-analysis | Q40850000 | ||
| Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes | Q41867314 | ||
| Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials | Q46097450 | ||
| Suicidality in pediatric patients treated with antidepressant drugs | Q46977975 | ||
| Validity of indirect comparisons in meta-analysis. | Q51924377 | ||
| Indirect comparisons: the mesh and mess of clinical trials | Q51929967 | ||
| Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors | Q51990048 | ||
| Random-effects meta-analyses are not always conservative | Q52915135 | ||
| Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression | Q53025930 | ||
| Bayesian measures of model complexity and fit | Q56532420 | ||
| Correction | Q61875124 | ||
| A comparison of statistical methods for combining event rates from clinical trials | Q69583295 | ||
| Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model | Q80166441 | ||
| Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes | Q81234350 | ||
| Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus | Q84521526 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clinical trial | Q30612 |
| meta-analysis | Q815382 | ||
| P304 | page(s) | 20-31 | |
| P577 | publication date | 2012-11-21 | |
| P1433 | published in | Clinical Trials | Q5133802 |
| P1476 | title | Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions | |
| Meta-analysis of clinical trial safety data in a drug development program: Answers to frequently asked questions | |||
| P478 | volume | 10 |
| Q39036481 | A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials |
| Q30885611 | Adaptive and repeated cumulative meta-analyses of safety data during a new drug development process |
| Q38950328 | An appraisal of meta-analysis guidelines: how do they relate to safety outcomes? |
| Q41424491 | Drug safety meta-analysis: promises and pitfalls. |
| Q46450711 | Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis |
| Q39973211 | Meta-analysis framework for exact inferences with application to the analysis of rare events |
| Q35857159 | Multivariate Meta-Analysis of Heterogeneous Studies Using Only Summary Statistics: Efficiency and Robustness |
| Q93243347 | On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies |
| Q35860102 | Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection. |
| Q38480274 | Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival |
| Q36164586 | The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations |
| Q24288962 | Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods |
| Q24185986 | Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews |
Search more.